Charles Duncan
Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.
Recent Quotes
"INO reported 2Q17 financial results, including $92M in cash prior to the recent $71M capital raise."
—
Charles Duncan, Piper Jaffray & Co.
(8/9/17)
more >
"We have recently performed additional diligence on INO's REVEAL and believe the program is well-designed to demonstrate clinically meaningful results which highlight potential advantages over surgery."
—
Charles Duncan, Piper Jaffray & Co.
(8/4/17)
more >
"INO announced the clinical hold has been lifted on its VGX-3100 cervical dysplasia program and it will now begin enrolling patients in the Phase III REVEAL studies."
—
Charles Duncan, Piper Jaffray & Co.
(6/8/17)
more >
"INO's 3112 can induce a T-cell response in a small group of HPV-associated H&N cancers."
—
Charles Duncan, Piper Jaffray & Co.
(5/18/17)
more >
"We see the main value-creating events as initiation of INO's Phase III in cervical dysplasia and data in HIV and Zika later this year."
—
Charles Duncan, Piper Jaffray & Co.
(5/11/17)
more >
"INO's revenues and R&D were slightly above our projections."
—
Charles Duncan, Piper Jaffray & Co.
(3/16/17)
more >
"Following today's updates we remain buyers of INO shares in anticipation of a smooth turn-around and 1H17 trial start for '3100, and upside from its Phase I Zika (4Q16) and Ebola (1H17) results."
—
Charles Duncan, Piper Jaffray & Co.
(11/9/16)
more >
"We believe INO's program can get back on track fairly quickly with a trial initiation as soon as 1H17."
—
Charles Duncan, Piper Jaffray & Co.
(10/24/16)
more >
